American Society of Clinical Oncology (ASCO)

Journal of Clinical Oncology

, volume 39 , issue 14 , pages 1553-1562

Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium

Jörg Beyer ¹

Laurence Collette ²

Nicolas Sauvé ²

Gedske Daugaard ³

Alexey Tryakin ^{4, 5}

Torgrim Tandstad ⁶

Alexey Tryakin ^{7, 8}

Olof Ståhl ⁹

E. González-Billalabeitia ^{10, 11}

Ugo De Giorgi ¹²

Stéphane Culine ¹³

Ronald de Wit ¹⁴

Aaron R. Hansen ¹⁵

Marko Bebek ¹⁶

Angelika Terbuch ¹⁷

Costantine Albany ¹⁸

Marcus Hentrich ¹⁹

Jourik Gietema ²⁰

H. Negaard ²¹

Robert Huddart ²²

Anja Lorch ^{23, 24}

Fay H. Cafferty ²⁵

Daniel Y C Heng ²⁶

Christopher Sweeney ²⁷

Eric Winquist ²⁸

Michal Chovanec ²⁹

Christian D. Fankhauser ³⁰

Daniel Stark ³¹

P. Grimison ³²

Andrea Necchi ³³

Ben Tran ³⁴

Axel Heidenreich ³⁵

Jonathan Shamash ³⁶

Cora N. Sternberg ³⁷

David J. Vaughn ³⁸

Ignacio Duran ³⁹

Carsten Bokemeyer ⁴⁰

Anna Patrikidou ⁴¹

R Cathomas ⁴²

Samson Assele ²

Silke Gillessen ^{43, 44, 45}

Hide authors affiliations Show authors affiliations: 45 affiliations

Department of Medical Oncology, Inselspital, University Hospital, University of Bern, Bern, Switzerland |

European Organisation for Research and Treatment of Cancer, Brussels, Belgium |

Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark |

⁴

MEMORIAL SLOAN KETTERING CANCER CENTER, NEW YORK, NY |

⁵

Weill Medical College of Cornell University, New York, NY |

⁶

The Cancer Clinic, St Olavs University Hospital and Department of Clinical and Molecular Medicine, The Norwegian University of Science and Technology, Trondheim, Norway

Norwegian University of Science and Technology

St Olav's University Hospital

⁷

N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation |

⁸

Research Institute of Oncology at Bashkir State Medical University, Ufa, Russian Federation |

⁹

Department of Oncology, Skåne University Hospital, Lund, Sweden |

¹⁰

Servicio de Oncologia Medica, Hospital Universitario 12 de Octubre, Madrid, Spain |

¹¹

Universidad Catolica San Antonio de Murcia, UCAM, Murcia, Spain |

¹²

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy and the Italian Germ Cell Cancer Group (IGG), Italy

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

Institute of Geosciences and Earth Resources

¹³

Department of Medical Oncology, Hôpital Saint-Louis, AP-HP, Faculté de Paris, Paris, France |

¹⁴

Erasmus MC Cancer Institute, Rotterdam, The Netherlands |

¹⁵

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, CANADA |

¹⁶

Department of Oncology, University Hospital Centre Zagreb, Zagreb, Croatia |

¹⁷

Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria |

¹⁸

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN |

¹⁹

Department of Hematology and Oncology, Red Cross Hospital, University of Munich, Munich, Germany |

²⁰

University Medical Center Groningen, Groningen, the Netherlands |

²¹

Department of oncology, Oslo university hospital, Oslo, Norway |

²²

Institute of Cancer research, Sutton, United Kingdom |

²³

Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland |

²⁴

Department of Urology, University Hospital Dusseldorf, Dusseldorf, Germany |

²⁵

Medical Research Council Clinical Trials Unit at University College London (UCL), London, United Kingdom |

²⁶

Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada |

²⁷

Department of Medical oncology, Dana-Farber Cancer Institute, BOSTON, MA |

²⁸

Division of Medical Oncology, Western University and London Health Sciences Centre, London, Ontario, Canada |

²⁹

2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava, Slovakia

Comenius University Bratislava

National Cancer Institute (Slovakia)

³⁰

University of Zurich, Zurich, SWITZERLAND |

³¹

Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom |

³²

Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Sydney, Australia |

³³

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Current Affiliation: Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy |

³⁴

Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia |

³⁵

Department of Urology, Uro-Oncology, Robot-Assisted and Specialized Urologic Surgery, University Hospital Cologne, Cologne, Germany |

³⁶

St Bartholomew's Hospital, London, United Kingdom |

³⁷

Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy. Current affiliation: Englander Institute for Precision Medicine, Weill Cornell Medicine, New York-Presbyterian, New York, NY

Cornell University

NewYork-Presbyterian Hospital

³⁸

University of Pennsylvania, philadelphia, PA |

³⁹

Hospital Universitario Marques de Valdecilla and IDIVAL, Santander, Spain

Marqués de Valdecilla University Hospital

Instituto de Investigación Marqués de Valdecilla

⁴⁰

Department of Oncology, Hematology and BMT with Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany |

⁴¹

Department of Oncology, Geneva University Hospital, Geneva, Switzerland. Current affiliation: Sarah Cannon Research Institute and UCL Cancer Institute, London, United Kingdom |

⁴²

Division of Oncology/Hematology, Cantonal Hospital Graubunden, Chur, Switzerland |

⁴³

Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland |

⁴⁴

Universita della Svizzera Italiana, Lugano, Switzerland |

⁴⁵

University Of Manchester, Manchester, United Kingdom |

Publication type: Journal Article

Publication date: 2021-05-10

American Society of Clinical Oncology (ASCO)

Journal of Clinical Oncology

scimago Q1

wos Q1

SJR: 11.205

CiteScore: 38.9

Impact factor: 41.9

ISSN: 0732183X, 15277755

DOI: 10.1200/jco.20.03292

Copy DOI

PubMed ID: 33729863

Cancer Research

Oncology

Abstract

PURPOSE

The classification of the International Germ-Cell Cancer Collaborative Group (IGCCCG) has been a major advance in the management of germ-cell tumors, but relies on data of only 660 patients with seminoma treated between 1975 and 1990. We re-evaluated this classification in a database from a large international consortium.

MATERIALS AND METHODS

Data on 2,451 men with metastatic seminoma treated with cisplatin- and etoposide-based first-line chemotherapy between 1990 and 2013 were collected from 30 institutions or collaborative groups in Australia, Europe, and North America. Clinical trial and registry data were included. Primary end points were progression-free survival (PFS) and overall survival (OS) calculated from day 1 of treatment. Variables at initial presentation were evaluated for their prognostic impact. Results were validated in an independent validation set of 764 additional patients.

RESULTS

Compared with the initial IGCCCG classification, in our modern series, 5-year PFS improved from 82% to 89% (95% CI, 87 to 90) and 5-year OS from 86% to 95% (95% CI, 94 to 96) in good prognosis, and from 67% to 79% (95% CI, 70 to 85) and 72% to 88% (95% CI, 80 to 93) in intermediate prognosis patients. Lactate dehydrogenase (LDH) proved to be an additional adverse prognostic factor. Good prognosis patients with LDH above 2.5× upper limit of normal had a 3-year PFS of 80% (95% CI, 75 to 84) and a 3-year OS of 92% (95% CI, 88 to 95) versus 92% (95% CI, 90 to 94) and 97% (95% CI, 96 to 98) in the group with lower LDH.

CONCLUSION

PFS and OS in metastatic seminoma significantly improved in our modern series compared with the original data. The original IGCCCG classification retains its relevance, but can be further refined by adding LDH at a cutoff of 2.5× upper limit of normal as an additional adverse prognostic factor.

Found

2 citations

Kojo Kosuke

62 publications, 135 citations, 116 reviews

h-index: 6

University of Tsukuba Hospital

University of Tsukuba

International University of Health and Welfare

Top-30

Journals

	2 4 6 8 10
Frontiers in Oncology	Frontiers in Oncology, 10, 7.3% Frontiers in Oncology 10 publications, 7.3%
Clinical Genitourinary Cancer	Clinical Genitourinary Cancer, 8, 5.84% Clinical Genitourinary Cancer 8 publications, 5.84%
Journal of Clinical Oncology	Journal of Clinical Oncology, 4, 2.92% Journal of Clinical Oncology 4 publications, 2.92%
Cancers	Cancers, 3, 2.19% Cancers 3 publications, 2.19%
World Journal of Urology	World Journal of Urology, 3, 2.19% World Journal of Urology 3 publications, 2.19%
European Urology Open Science	European Urology Open Science, 3, 2.19% European Urology Open Science 3 publications, 2.19%
JCO Oncology Practice	JCO Oncology Practice, 3, 2.19% JCO Oncology Practice 3 publications, 2.19%
Human Pathology	Human Pathology, 2, 1.46% Human Pathology 2 publications, 1.46%
European Urology	European Urology, 2, 1.46% European Urology 2 publications, 1.46%
Urology Case Reports	Urology Case Reports, 2, 1.46% Urology Case Reports 2 publications, 1.46%
Urologic Clinics of North America	Urologic Clinics of North America, 2, 1.46% Urologic Clinics of North America 2 publications, 1.46%
International Journal of Clinical Oncology	International Journal of Clinical Oncology, 2, 1.46% International Journal of Clinical Oncology 2 publications, 1.46%
Cancer	Cancer, 2, 1.46% Cancer 2 publications, 1.46%
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 2, 1.46% International Journal of Molecular Sciences 2 publications, 1.46%
Tumor Diagnostik und Therapie	Tumor Diagnostik und Therapie, 2, 1.46% Tumor Diagnostik und Therapie 2 publications, 1.46%
Onkourologiya	Onkourologiya, 2, 1.46% Onkourologiya 2 publications, 1.46%
Medicina	Medicina, 2, 1.46% Medicina 2 publications, 1.46%
BMC Cancer	BMC Cancer, 2, 1.46% BMC Cancer 2 publications, 1.46%
International Journal of Cancer	International Journal of Cancer, 2, 1.46% International Journal of Cancer 2 publications, 1.46%
Histopathology	Histopathology, 2, 1.46% Histopathology 2 publications, 1.46%
Clinical and Translational Oncology	Clinical and Translational Oncology, 2, 1.46% Clinical and Translational Oncology 2 publications, 1.46%
Scientific Reports	Scientific Reports, 2, 1.46% Scientific Reports 2 publications, 1.46%
European urology oncology	European urology oncology, 2, 1.46% European urology oncology 2 publications, 1.46%
Baylor University Medical Center Proceedings	Baylor University Medical Center Proceedings, 1, 0.73% Baylor University Medical Center Proceedings 1 publication, 0.73%
JMIR Cancer	JMIR Cancer, 1, 0.73% JMIR Cancer 1 publication, 0.73%
Oncology Letters	Oncology Letters, 1, 0.73% Oncology Letters 1 publication, 0.73%
Surgical Case Reports	Surgical Case Reports, 1, 0.73% Surgical Case Reports 1 publication, 0.73%
CMAJ Open	CMAJ Open, 1, 0.73% CMAJ Open 1 publication, 0.73%
Journal of Cancer Research and Clinical Oncology	Journal of Cancer Research and Clinical Oncology, 1, 0.73% Journal of Cancer Research and Clinical Oncology 1 publication, 0.73%
	2 4 6 8 10

Publishers

	5 10 15 20 25 30 35 40
Elsevier	Elsevier, 38, 27.74% Elsevier 38 publications, 27.74%
Springer Nature	Springer Nature, 28, 20.44% Springer Nature 28 publications, 20.44%
Wiley	Wiley, 13, 9.49% Wiley 13 publications, 9.49%
Frontiers Media S.A.	Frontiers Media S.A., 11, 8.03% Frontiers Media S.A. 11 publications, 8.03%
MDPI	MDPI, 10, 7.3% MDPI 10 publications, 7.3%
American Society of Clinical Oncology (ASCO)	American Society of Clinical Oncology (ASCO), 7, 5.11% American Society of Clinical Oncology (ASCO) 7 publications, 5.11%
Taylor & Francis	Taylor & Francis, 4, 2.92% Taylor & Francis 4 publications, 2.92%
SAGE	SAGE, 3, 2.19% SAGE 3 publications, 2.19%
Georg Thieme Verlag KG	Georg Thieme Verlag KG, 3, 2.19% Georg Thieme Verlag KG 3 publications, 2.19%
AME Publishing Company	AME Publishing Company, 3, 2.19% AME Publishing Company 3 publications, 2.19%
JMIR Publications	JMIR Publications, 2, 1.46% JMIR Publications 2 publications, 1.46%
Publishing House ABV Press	Publishing House ABV Press, 2, 1.46% Publishing House ABV Press 2 publications, 1.46%
S. Karger AG	S. Karger AG, 2, 1.46% S. Karger AG 2 publications, 1.46%
Ovid Technologies (Wolters Kluwer Health)	Ovid Technologies (Wolters Kluwer Health), 2, 1.46% Ovid Technologies (Wolters Kluwer Health) 2 publications, 1.46%
Spandidos Publications	Spandidos Publications, 1, 0.73% Spandidos Publications 1 publication, 0.73%
CMA Impact Inc.	CMA Impact Inc., 1, 0.73% CMA Impact Inc. 1 publication, 0.73%
BMJ	BMJ, 1, 0.73% BMJ 1 publication, 0.73%
American Association for Cancer Research (AACR)	American Association for Cancer Research (AACR), 1, 0.73% American Association for Cancer Research (AACR) 1 publication, 0.73%
AOSIS	AOSIS, 1, 0.73% AOSIS 1 publication, 0.73%
American Medical Association (AMA)	American Medical Association (AMA), 1, 0.73% American Medical Association (AMA) 1 publication, 0.73%
	5 10 15 20 25 30 35 40

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

137

Cite this

GOST |

Cite this

GOST Copy

Beyer J. et al. Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium // Journal of Clinical Oncology. 2021. Vol. 39. No. 14. pp. 1553-1562.

GOST all authors (up to 50) Copy

Beyer J., Collette L., Sauvé N., Daugaard G., Tryakin A., Tandstad T., Tryakin A., Ståhl O., González-Billalabeitia E., De Giorgi U., Culine S., de Wit R., Hansen A. R., Bebek M., Terbuch A., Albany C., Hentrich M., Gietema J., Negaard H., Huddart R., Lorch A., Cafferty F. H., Heng D. Y. C., Sweeney C., Winquist E., Chovanec M., Fankhauser C. D., Stark D., Grimison P., Necchi A., Tran B., Heidenreich A., Shamash J., Sternberg C. N., Vaughn D. J., Duran I., Bokemeyer C., Patrikidou A., Cathomas R., Assele S., Gillessen S. Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium // Journal of Clinical Oncology. 2021. Vol. 39. No. 14. pp. 1553-1562.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1200/jco.20.03292

UR - https://doi.org/10.1200/jco.20.03292

TI - Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium

T2 - Journal of Clinical Oncology

AU - Beyer, Jörg

AU - Collette, Laurence

AU - Sauvé, Nicolas

AU - Daugaard, Gedske

AU - Tryakin, Alexey

AU - Tandstad, Torgrim

AU - Tryakin, Alexey

AU - Ståhl, Olof

AU - González-Billalabeitia, E.

AU - De Giorgi, Ugo

AU - Culine, Stéphane

AU - de Wit, Ronald

AU - Hansen, Aaron R.

AU - Bebek, Marko

AU - Terbuch, Angelika

AU - Albany, Costantine

AU - Hentrich, Marcus

AU - Gietema, Jourik

AU - Negaard, H.

AU - Huddart, Robert

AU - Lorch, Anja

AU - Cafferty, Fay H.

AU - Heng, Daniel Y C

AU - Sweeney, Christopher

AU - Winquist, Eric

AU - Chovanec, Michal

AU - Fankhauser, Christian D.

AU - Stark, Daniel

AU - Grimison, P.

AU - Necchi, Andrea

AU - Tran, Ben

AU - Heidenreich, Axel

AU - Shamash, Jonathan

AU - Sternberg, Cora N.

AU - Vaughn, David J.

AU - Duran, Ignacio

AU - Bokemeyer, Carsten

AU - Patrikidou, Anna

AU - Cathomas, R

AU - Assele, Samson

AU - Gillessen, Silke

PY - 2021

DA - 2021/05/10

PB - American Society of Clinical Oncology (ASCO)

SP - 1553-1562

IS - 14

VL - 39

PMID - 33729863

SN - 0732-183X

SN - 1527-7755

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2021_Beyer,

author = {Jörg Beyer and Laurence Collette and Nicolas Sauvé and Gedske Daugaard and Alexey Tryakin and Torgrim Tandstad and Alexey Tryakin and Olof Ståhl and E. González-Billalabeitia and Ugo De Giorgi and Stéphane Culine and Ronald de Wit and Aaron R. Hansen and Marko Bebek and Angelika Terbuch and Costantine Albany and Marcus Hentrich and Jourik Gietema and H. Negaard and Robert Huddart and Anja Lorch and Fay H. Cafferty and Daniel Y C Heng and Christopher Sweeney and Eric Winquist and Michal Chovanec and Christian D. Fankhauser and Daniel Stark and P. Grimison and Andrea Necchi and Ben Tran and Axel Heidenreich and Jonathan Shamash and Cora N. Sternberg and David J. Vaughn and Ignacio Duran and Carsten Bokemeyer and Anna Patrikidou and R Cathomas and Samson Assele and Silke Gillessen},

title = {Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium},

journal = {Journal of Clinical Oncology},

year = {2021},

volume = {39},

publisher = {American Society of Clinical Oncology (ASCO)},

month = {may},

url = {https://doi.org/10.1200/jco.20.03292},

number = {14},

pages = {1553--1562},

doi = {10.1200/jco.20.03292}

}

MLA

Cite this

MLA Copy

Beyer, Jörg, et al. “Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium.” Journal of Clinical Oncology, vol. 39, no. 14, May. 2021, pp. 1553-1562. https://doi.org/10.1200/jco.20.03292.

Publisher

American Society of Clinical Oncology (ASCO)

Journal

Journal of Clinical Oncology

scimago Q1

wos Q1

SJR

11.205

CiteScore

38.9

Impact factor

41.9

ISSN

0732183X (Print)

15277755 (Electronic)